marked.bio

Company

LaNova Medicines Zhejiang

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

LM-302 2apatinib 2toripalimab 1nivolumab 1tislelizumab 1anlotinib 1benmelstobart 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

2 of 3 trials shown

  1. LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

    Active, not recruiting Phase 3 LaNova Medicines Zhejiang Started 2024Primary completion 2026-11 NCT06351020

    LM-302apatinibirinotecan

    Centrally confirmed CLDN18.2-positive

    Claudin 18.2 expressionLocally Advanced or Metastatic GC and GCJ Adenocarcinoma

  2. A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

    Recruiting Phase 2 LaNova Medicines Zhejiang Started 2023Primary completion 2031-08 NCT05934331

    LM-302toripalimabcapecitabineTegafur, Gimeracil and Oteracil Potassium Capsulesnivolumabapatinibgemcitabinetislelizumabanlotinibbenmelstobart

    CLDN18.2-positive subjects.

    Claudin 18.2 expressionMalignant Neoplasms of Digestive Organs